NEW YORK, March 30 (Reuters) - Prostate cancer vaccine Provenge has long incited passions unlike any other cancer therapy. Doctors who raised doubts about it received death threats. Health regulators ...
November 18, 2010 — The prostate cancer vaccine sipuleucel-T (Provenge, Dendreon) received a middling vote of confidence for its on-label use and what amounted to a thumbs-down vote for its off-label ...
Dendreon filed for bankruptcy protection on Monday after sales of Provenge fell way short of expectations and the company could not pay off a huge debt coming due. By Andrew Pollack Costly treatments ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Georgia Health Sciences University is recruiting patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results